When SGMO will get FDA approvals in future dates

**Sangamo Therapeutics is anticipated to seek FDA approval for its Fabry gene therapy candidate, isaralgagene civaparvovec, in the second half of 2025.** Here's the rationale behind this timeline: 1. **Data Availability**: The complete dataset to support the Accelerated Approval pathway will be available in the first half of 2025. 2. **Submission Timeline**: Sangamo expects to file the Biologics License Application (BLA) in the second half of 2025. 3. **FDA Review Process**: The FDA's alignment on an accelerated approval pathway indicates a clear regulatory direction that typically precedes the submission of a BLA and the subsequent review process. Given these points, it is reasonable to expect that Sangamo Therapeutics will pursue FDA approval for isaralgagene civaparvovec in the second half of 2025.